Skip to main content
SpringerLink
Log in

Feasibility and reliability of health-related quality of life measurements among tuberculosis patients

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

The dramatic global impact of tuberculosis on mortality has been well documented, but its impact on morbidity has not been well described. The emphasis on treatment of latent tuberculosis (TB) infection highlights the tradeoff between short-term decrements in health status from ‘preventive’ therapy, and long-term gains related to fewer cases of active TB. However, these changes in health status have not been characterized. As a first step, we examined the feasibility and reliability of administering two health status questionnaires, in a multicultural TB clinic setting. The Medical Outcomes Study SF-36 and the EuroQOL EQ-5D were self-administered during 3 weekly interviews. One hundred and eighty-six potentially eligible patients were identified, of whom 112 could be evaluated; 106 (57%) were confirmed eligible. Sixty-seven (63%) agreed to participate; 24 (36%) were women. Fifty-three participants (79%) were foreign-born, with median residence in Canada of 3.5 years. Fifty (75%) of the participants completed all study measurements: 25 were treated for latent TB, 17 for active TB, and eight had previous active TB. Cronbach's α coefficients ranged from 0.73 to 0.94 for the SF-36 domain scores. Intraclass correlation coefficients were 0.66 for the SF-36 physical component summary, 0.79 for the mental component summary, and 0.73 for the EQ-5D. These instruments appeared reliable in a highly selected group of TB patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. World Health Organisation. Global Tuberculosis Control. WHO Report 2001. Geneva: WHO, 2001.

    Google Scholar 

  2. Njoo H, Nault P, Phypers M. Tuberculosis in Canada, 1998. Ottawa: Health Canada, 2001.

    Google Scholar 

  3. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis 1990; 142(4): 848-853.

    Google Scholar 

  4. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127(12): 1051-1061.

    Google Scholar 

  5. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: Take it or leave it. Am Rev Respir Dis 1988; 137(1): 215-220.

    Google Scholar 

  6. Geiter L (ed.), for the Committee on the Elimination of Tuberculosis in the United States. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington: Washington National Press Academy, 2000.

  7. American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Cri Care Med 2000; 161(4): S222-S247.

    Google Scholar 

  8. Canadian Lung Association/Health Canada. In: Long R (ed.), Canadian Tuberculosis Standards, 5th ed. Ottawa: Canadian Lung Association, 2000.

    Google Scholar 

  9. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.

    Google Scholar 

  10. Dasgupta K, Schwartzman K, Marchand R, Tannenbaum T, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born population. Am J Respir Crit Care Med 2000; 162: 2079-2086.

    Google Scholar 

  11. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1311-1320.

    Google Scholar 

  12. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: Medical Outcomes Trust, 1993.

    Google Scholar 

  13. Ware JEJ, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scale: A User's Manual. 5th ed. Boston: Medical Outcome Trust, 1994.

    Google Scholar 

  14. Wood-Dauphinee S, Gauthier L, Gandek B, Magnan L, Pierre U. Readying a US measure of health status, the SF-36, for use in Canada. Clin Invest Med 1997; 20(4): 224-238.

    Google Scholar 

  15. EuroQol group. A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.

    Google Scholar 

  16. Brooks R. EuroQol: The current state of play. Health Policy 1996; 37: 53-72.

    Google Scholar 

  17. Mayo NE. Goldberg M, Kind P. Calibrating the ED-5D for a Canadian population. Proceedings from EuroQol Plenary Meeting Rotterdam 1997. Rotterdam: Center for Health Policy and Law, Erasmus University, 1998; 25-40.

    Google Scholar 

  18. Dion M, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Measurement of health preferences among patients with tuberculous infection and disease. Med Decision Making 2002 22[Suppl]: S102-S114.

    Google Scholar 

  19. Rosner B. Fundamentals of Biostatistics. 3rd ed. Belmont: Duxbury Press, 1990.

    Google Scholar 

  20. Drummond MF, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Toronto: Oxford Medical Publications, 1997.

    Google Scholar 

  21. Streiner DL, Norman GR. Health Measurement Scales. A Practical Guide to Their Developement and Use. 2nd ed. New York: Oxford medical publications, 1995.

    Google Scholar 

  22. Kramer MS, Feinstein AR. Clinical biostatistics LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981; 29(1): 111-123.

    Google Scholar 

  23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33(1): 159-174.

    Google Scholar 

  24. Stata Statistical Software: Release 6.0 [computer program]. Stata Corporation. College Station, Texas: Stata Corporation, 1999.

  25. Donner A, Eliasziw M. Sample size requirements for reliability studies. Stat Med 1987; 6(4): 441-448.

    Google Scholar 

  26. Bouchet C, Guillemin F, Paul-Dauphin A, Briancon S. Selection of quality-of-life measures for a prevention trial: A psychometric analysis. Cont Clin Trials 2000; 21(1): 30-43.

    Google Scholar 

  27. Dorman PJ, Slattery J, Farrell B, Dennis MS, Sandercock, PA. A randomised comparison of the EuroQol and Short Form-36 after stroke. Br Med J 1997; 315(7106): 461.

    Google Scholar 

  28. Rivest P, Tannenbaum T, Bedard L. Epidemiology of tuberculosis in Montreal. CMAJ 1998; 158(5): 605-609.

    Google Scholar 

  29. Jenkins CD. Assessment of outcomes of health intervention. Soc Sci Med 1992; 35(4): 367-375.

    Google Scholar 

  30. Vissandjee B, Dupere S. Culture, migration et instrument de mesure: défís incontournables. J Int Migrat Integrat 2001; 1(4): 477-492.

    Google Scholar 

  31. Wagner AK, Gandek B, Aaronson NK, et al. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 925-932.

    Google Scholar 

  32. Chang DF, Chun CA, Takeuchi DT, Shen H. SF-36 health survey: tests of data quality, scaling assumptions, and reliability in a community sample of Chinese Americans. Med Care 2000; 38(5): 542-548.

    Google Scholar 

  33. Chie WC, Huang CS, Chen JH, Chang KJ. Measurement of the quality of life during different clinical phases of breast cancer. J Formosan Med Assoc 1999; 98(4): 254-260.

    Google Scholar 

  34. Arocho R, McMillan CA, Sutton-Wallace P. Construct validation of the USA-Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998; 7(2): 121-126.

    Google Scholar 

  35. Thumboo J, Fong KY, Ng TP, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26(1): 97-102.

    Google Scholar 

  36. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. CMAJ 2000; 163(3): 265-271.

    Google Scholar 

  37. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: Reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997; 50(1): 79-93.

    Google Scholar 

  38. Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford) 1999; 38(9): 807-813.

    Google Scholar 

  39. Dorman P, Slattery J, Farrell B, Dennis M, Sandercock P. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke 1998; 29(1): 63-68.

    Google Scholar 

  40. American Thoracic Society and the Centers for Disease Control and Prevention. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.

    Google Scholar 

  41. Dorman PJ, Dennis M, Sandercock P. How do scores on the EuroQol relate to scores on the SF-36 after stroke? Stroke 1999; 30(10): 2146-2151.

    Google Scholar 

  42. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999; 8(1-2): 9-16.

    Google Scholar 

  43. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-741.

    Google Scholar 

  44. Tuberculosis Trials Consortium. The Tuberculosis Trials Consortium: A model for clinical trials collaborations. Public Health Reports 2001; 116[Suppl 1]: 41-49.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Respiratory Epidemiology Unit, McGill University, Canada

    M.-J. Dion, J. Bourbeau, D. Menzies & K. Schwartzman

  2. Respiratory Division, McGill University Health Center, Canada

    M.-J. Dion, J. Bourbeau, D. Menzies & K. Schwartzman

  3. Department of Epidemiology and Biostatistics, McGill University, Canada

    M.-J. Dion, P. Tousignant, J. Bourbeau, D. Menzies & K. Schwartzman

  4. Direction de la Santé Publique, Montréal-Centre, Montreal, Canada

    P. Tousignant

Authors
  1. M.-J. Dion
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Tousignant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Bourbeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Menzies
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Schwartzman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dion, MJ., Tousignant, P., Bourbeau, J. et al. Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. Qual Life Res 13, 653–665 (2004). https://doi.org/10.1023/B:QURE.0000021320.89524.64

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:QURE.0000021320.89524.64

Search

Navigation